Two Sigma Investments LP boosted its position in Audentes Therapeutics Inc (NASDAQ:BOLD) by 277.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 128,707 shares of the biotechnology company’s stock after purchasing an additional 94,565 shares during the period. Two Sigma Investments LP’s holdings in Audentes Therapeutics were worth $4,022,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in BOLD. State Street Corp grew its stake in Audentes Therapeutics by 231.6% in the 2nd quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock worth $4,234,000 after acquiring an additional 154,544 shares during the period. The Manufacturers Life Insurance Company grew its stake in Audentes Therapeutics by 1,086.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock worth $260,000 after acquiring an additional 12,435 shares during the period. California State Teachers Retirement System grew its stake in Audentes Therapeutics by 128.8% in the 2nd quarter. California State Teachers Retirement System now owns 27,000 shares of the biotechnology company’s stock worth $517,000 after acquiring an additional 15,200 shares during the period. Russell Investments Group Ltd. purchased a new stake in Audentes Therapeutics in the 3rd quarter worth approximately $808,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics during the 3rd quarter valued at $143,000. 66.96% of the stock is owned by hedge funds and other institutional investors.
Shares of Audentes Therapeutics Inc (NASDAQ BOLD) opened at $29.18 on Monday. Audentes Therapeutics Inc has a 12 month low of $13.90 and a 12 month high of $41.80. The stock has a market cap of $1,070.15, a price-to-earnings ratio of -8.58 and a beta of 0.89.
BOLD has been the subject of several research reports. BidaskClub cut shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 15th. HC Wainwright set a $37.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 11th. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Mizuho initiated coverage on shares of Audentes Therapeutics in a research note on Monday, February 12th. They set a “neutral” rating and a $26.00 price objective for the company. Finally, William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a research note on Friday, March 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $35.56.
In related news, major shareholder Orbimed Advisors Llc sold 421,638 shares of Audentes Therapeutics stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.17, for a total transaction of $14,829,008.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 1,069,707 shares of company stock worth $37,499,461 in the last 90 days. Company insiders own 47.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3302268/audentes-therapeutics-inc-bold-holdings-increased-by-two-sigma-investments-lp.html.
Audentes Therapeutics Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.